Letters to the Editor

OnabotulinumtoxinA Injections for Chronic Migraine Prophylaxis

Original Article: Migraine Headache Prophylaxis
Issue Date: January 1, 2019
See additional reader comments at: https://www.aafp.org/afp/2019/0101/p17.html

To the Editor: We appreciated this article on migraine headache prophylaxis from Drs. Ha and Gonzalez. Because of the prevalence of migraine headaches, we would like to elaborate on the role of onabotulinumtoxinA (Botox) injections for chronic migraines. This is an office-based procedure that can be performed by family physicians and can provide great relief to patients. Largely because of cost, it should be reserved for patients who have chronic migraines (not episodic migraines or tension-type headaches) and who have had no success with daily prophylactic therapies.

According to the American Academy of Neurology, onabotulinumtoxinA should be offered to patients with chronic migraines, with the goal of increasing the number of headache-free days and reducing impact on health-related quality of life.1 These recommendations are based on two randomized trials that showed a statistically significant decrease in the frequency of headache days.2,3 Since then, other studies have demonstrated its tolerability, safety, and effectiveness in the treatment of chronic migraines.4,5 One study also demonstrated the cost-effectiveness of the injections through a reduction in urgent care/emergency department visits and hospitalizations.6

The onabotulinumtoxinA injection procedure comprises superficial injections into 31 mapped sites. They are generally well-tolerated, and patients can return to normal activity the same day. The most common adverse effects reported are neck pain, muscle weakness, eyelid ptosis, and injection-site pain. This treatment is a relatively easy in-office primary care procedure that can provide significant pain relief to patients with chronic migraine headaches.

Eric Carter, MD
Fort Belvoir, Va.

Edward Kwon, MD
Fort Belvoir, Va.
Email: eddiekwon6@yahoo.com

Author disclosure: No relevant financial affiliations.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, Department of the Air Force, Department of Defense, or the U.S. government.

References


This letter was sent to the authors of “Migraine Headache Prophylaxis,” who declined to reply.
LETTERS TO THE EDITOR

Substance Use Disorders: Considerations in Maternity and Neonatal Care

Original Article: Primary Care for Persons Who Inject Drugs
Issue Date: January 15, 2019
See additional reader comments at: https://www.aafp.org/afp/2019/0115/p109.html

To the Editor: I appreciated this article, but the review did not include discussion of maternal or child health. As primary care physicians who care for the mother/child dyad, family physicians are uniquely situated to provide comprehensive and longitudinal care for women and children affected by substance use disorders.

As many as 85% of pregnancies in women with opioid use disorder are unintended.1 The rate of opioid use during pregnancy is 5.6 per 1,000 live births.2 In women with confirmed substance use disorder, physicians should discuss planning for pregnancy and offer the full spectrum of contraceptive options, including emergency contraception, and especially long-acting contraceptives.

The American College of Obstetricians and Gynecologists recommends using a verbal screening tool, such as the 4 P’s (parents, partners, past, present), NIDA (National Institute on Drug Abuse) Quick Screen, or CRAFFT (car, relax, alone, forget, family, trouble), at the initial prenatal appointment.2 Screening should include alcohol, tobacco, and prescription and illicit drug use. Patients who screen positive for substance use disorder should be offered a brief intervention, motivational interviewing, and referral to treatment. Pregnant patients with opioid use disorder should have broadened sexually transmitted infection screening and should be screened for coexisting mental health disorders.1,3

The American College of Obstetricians and Gynecologists recommends opioid agonist therapy for pregnant patients with opioid use disorder.1 Opioid agonist therapy prevents withdrawal symptoms, prevents illicit use and associated morbidity and mortality, and improves adherence to prenatal care. The combination of prenatal care and opioid agonist therapy reduces the risk of obstetric complications. If the patient is already undergoing opioid agonist therapy with methadone, buprenorphine, or buprenorphine/naloxone film (Suboxone), that treatment plan should continue. Evidence is growing that extended-release injectable naltrexone (Vivitrol) is also safe to continue during pregnancy. Because the risk of relapse is high and withdrawal has been correlated with increased miscarriage rates, withdrawing from opioids is not recommended. If the patient insists on withdrawing from opioids, it should be done in a supervised medical setting.1,3

There has been a sharp increase in neonatal abstinence syndrome, from 1.5 cases per 1,000 hospital births in 1999 to 6 cases per 1,000 hospital births in 2013.4 Symptoms of neonatal abstinence syndrome include irritability; jitteriness; tremors; difficulty sleeping; being inconsolable; high-pitched crying; exaggerated Moro reflex; hypertonia; and myoclonic jerks. Poor feeding and weight loss may also occur in infants born to mothers with opioid use disorder. Breastfeeding and skin-to-skin contact improve symptoms, reduce the need for pharmacotherapy, and shorten neonatal hospitalization. Breastfeeding should be encouraged in patients who are stable on opioid agonists, not using illicit drugs, and have no other contraindications (e.g., HIV infection).5

MaryAnn Dakkak, MD, MSPH
Boston, Mass.
Email: Maryann.dakkak@bmc.org

Author disclosure: No relevant financial affiliations.

References

In Reply: We appreciate Dr. Dakkak’s commentary regarding our article. We agree that the myriad of possible adverse effects from injection drug use during pregnancy necessitates an evaluation for pregnancy status and a discussion of contraception options as part of the complete evaluation and care of these patients. Given the rising prevalence of opioid use disorder during pregnancy,
LETTERS TO THE EDITOR

LETTERS TO THE EDITOR

a comprehensive review of opioid agonist phar-
macotherapy during pregnancy, intrapartum
and postpartum management, and neonatal
abstinence syndrome would be of value to family
physicians who often care for these patients.

Adam Visconti, MD, MPH
Washington, DC
Email: adam.visconti@dc.gov

Author disclosure: No relevant financial affiliations.

Thessaly vs. McMurray Test for Diagnosis
of Meniscal Injuries

Original Article: Knee Pain in Adults and Adoles-
cents: The Initial Evaluation
Issue Date: November 1, 2018
See additional reader comments at: https://www.aafp.org/afp/2018/1101/p576.html

To the Editor: In this article on knee pain in
adults, the authors contend that the Thessaly
test is an accurate test for diagnosing meniscal
injury. A 2012 article in American Family Phy-
sician1 reached similar conclusions regarding
the Thessaly test. This was a reasonable conclu-
sion based on the evidence available at the time;
however, the patients in the studies cited in that
article were diagnosed and treated at referral
centers with high prevalence rates of meniscal
injuries. Since 2012, additional evidence has sug-
gested that the Thessaly test is not as accurate as
initially reported.

A systematic review and meta-analysis of stud-
ies available through the end of 20142 concluded
that the Thessaly test has similar, and perhaps
slightly superior, accuracy when compared to the
McMurray and joint line tenderness tests. How-
ever, the authors concluded that none of the three
tests are particularly accurate for diagnosing
meniscal injuries.

More recent studies have produced results that
make us further question the accuracy of the
Thessaly test (see accompanying table2-5).

The evidence summarized in the table indi-
cates that the initial results of high accuracy of
the Thessaly test are not replicated in later stud-
ies. The outlying results reported by Grover1
may be explained in part by nonblinded exam-
iners as well as a test population skewed toward
high pretest probability of meniscal injury. We
conclude, contrary to assertions in the reference
article, that the Thessaly test is nonsuperior to the

| TABLE |

Accuracy of Thessaly and McMurray Tests for Detecting Meniscal Injuries

<table>
<thead>
<tr>
<th>Study</th>
<th>Test</th>
<th>Number of patients</th>
<th>LR+</th>
<th>LR–</th>
<th>Probability of meniscal injury if test is positive*</th>
<th>Probability of meniscal injury if test is negative*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith, et al.</td>
<td>Thessaly</td>
<td>490</td>
<td>5.6</td>
<td>0.28</td>
<td>38.3%</td>
<td>3%</td>
</tr>
<tr>
<td></td>
<td>McMurray</td>
<td>1,234</td>
<td>3.2</td>
<td>0.52</td>
<td>26.2%</td>
<td>5.5%</td>
</tr>
<tr>
<td>Snoeker, et al.</td>
<td>Thessaly†</td>
<td>121</td>
<td>1.07</td>
<td>0.88</td>
<td>10.7%</td>
<td>8.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.91</td>
<td>1.12</td>
<td>9.2%</td>
<td>11.1%</td>
</tr>
<tr>
<td>Goossens, et al.</td>
<td>Thessaly</td>
<td>593</td>
<td>1.37</td>
<td>0.68</td>
<td>13.1%</td>
<td>7.0%</td>
</tr>
<tr>
<td></td>
<td>McMurray</td>
<td></td>
<td>1.27</td>
<td>0.67</td>
<td>12.4%</td>
<td>6.9%</td>
</tr>
<tr>
<td>Blyth, et al.</td>
<td>Thessaly (primary care)</td>
<td>282</td>
<td>1.08</td>
<td>0.87</td>
<td>10.7%</td>
<td>8.8%</td>
</tr>
<tr>
<td></td>
<td>McMurray (primary care)</td>
<td></td>
<td>1.33</td>
<td>0.74</td>
<td>12.9%</td>
<td>7.6%</td>
</tr>
</tbody>
</table>
|                | Thessaly (musculoskele-
| tal clinicians)  |                    | 1.38    | 0.691   | 13.3%                                              | 7.1%                                               |
|                | McMurray (musculo-
| skeletal clinicians) |                    | 1.72    | 0.50    | 15.9%                                              | 5.3%                                               |

LR+ = positive likelihood ratio; LR– = negative likelihood ratio.

*—Based on a pretest probability of 10%.

†—This study reported separate data for each of the two examiners.

Information from references 2-5.
McMurray test in the diagnosis of meniscal injuries. Moreover, there is little evidence to support using either of these maneuvers in the evaluation of knee pain, particularly in the primary care population.

Shaun Spielman, MD, CAQSM
F. Stuart Leeds, MD, MS
Dayton, Ohio
Email: shaun.spielman@wright.edu

**Author disclosure:** No relevant financial disclosures.

**References**


**In Reply:** Thank you for your careful review and consideration of our article. We welcome the opportunity for additional discussion of physical examination maneuvers in the initial evaluation of knee pain.

Physical examination techniques remain a challenge to accurately study. Patient selection, timing from injury, previous patient functional level, examination setting, provider skills/training, and concomitant injuries are all potential confounders.

Our assessment is based on the volume of papers suggestive of Thessaly being superior. Many additional references were ultimately not included in our article because of reference limitations. The article you cited supports our conclusion of higher sensitivity and specificity for Thessaly.1 Added to this are articles by Karachalios, et al., yielding 92% sensitivity and 96% specificity for Thessaly2; and Harrison, et al., yielding 90% sensitivity and 97% specificity.3

Our interpretation of the data surrounding Thessaly continues to support its use (strength of recommendation taxonomy rating C), but we also recommend it as a patient-controlled examination technique. This subtle difference can increase a patient’s comfort level and should not be overlooked.

We thank you for highlighting the challenges inherent in physical examination technique research as well as the ongoing debate about examinations in general.

Christopher W. Bunt, MD, FAAFP
Charleston, S.C.
Email: buntc@musc.edu
Christopher E. Jonas, DO, FAAFP
Jennifer G. Chang, MD
Bethesda, Md.

**Author disclosure:** No relevant financial affiliations.

**The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Defense, the U.S. Air Force Medical Service, the Uniformed Services University of the Health Sciences, or the U.S. Air Force at large.

**References**